---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-130489"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:24:04.673580+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quince settles $16.4M EIB debt for $5.5M, eliminates debt overhang

## Summary
- Paid $5.5M to settle ~$16.4M in EIB debt obligations, a discount of roughly $10.9M.
- All obligations under the Finance Documents are fully satisfied and discharged.
- CEO says settlement removes a substantial constraint on pursuing strategic alternatives.
- Company continues restructuring and evaluation of strategic alternatives including M&A.

## SEC filing metadata
- accession: 0001193125-26-130489
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526130489/0001193125-26-130489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526130489/d57124d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-130489
- JSON: https://secwatch.observer/filing/0001193125-26-130489.json
- Plain text: https://secwatch.observer/filing/0001193125-26-130489.txt

## Key facts
- Material Agreements
  Quince Therapeutics, Inc. terminated Finance Contract with European Investment Bank (EIB) valued at EUR 4,800,000, or approximately $5.5 million (effective 2026-03-27).
  - Action: termination
  - Agreement: credit facility
  - Counterparty: European Investment Bank (EIB)
  - Value: EUR 4,800,000, or approximately $5.5 million
  - Effective: 2026-03-27
  source text: As previously disclosed, Quince Therapeutics, Inc. (the “Company”), Quince Therapeutics S.p.A. (the “Borrower”), the European Investment Bank (the “EIB”) and other parties named therein previously entered into a finance contract dated July 24, 2020 (as amended and restated, the “Finance Contract”) and a related guarantee agreement in connection with the Finance Contract (the “Guarantee Agreement,” together with the Finance Contract, the “Finance Documents”). On March 27, 2026, the Company agreed to pay, on the Borrower’s behalf, EUR 4,800,000, or approximately $5.5 million, to the EIB in full settlement of the Borrower’s obligations under the Finance Documents. As a result of the Company’s payment of such amount, the Company’s and the Borrower’s obligations under the finance documents were deemed satisfied.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312526130489/0001193125-26-130489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.